Hybrid adenovirus-AAV virus and methods of use thereof
US5871982A · kind A · utility
286Cited by
12References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 25, 1997 |
| Grant date | Feb 16, 1999 |
| Priority date | — |
| Expiry date | Aug 25, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/008
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a hybrid vector construct which comprises a portion of an adenovirus, 5' and 3'ITR sequences from an AAV, and a selected transgene. Also provided is a hybrid virus linked via a polycation conjugate to an AAV rep gene to form a single particle. These trans-infection particles are characterized by high titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome. Also disclosed is the use of the hybrid vectors and viruses to produce large quantities of recombinant AAV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.